bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer

CAMBRIDGE, Mass. & TARRYTOWN, N.Y.-- --Aug 6, 2018--bluebird bio, Inc. and Regeneron Pharmaceuticals, Inc. today announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer.
https://www.galvnews.com/news_ap/business/article_f83d7be3-f188-5325-89e2-f151047eddb8.html